

An Overview of the Bioactive Properties of Benzimidazole Derivatives

Kajal Gharat¹, Aditi Ghara², Komal Patil³, Prachi Mokal⁴, Sajid F. Shaikh⁵,
Maryappa C Sonawale⁶, Amod N. Thakkar⁷

Student P. G. Department of Chemistry, Veer Wajekar ASC Collage Phunde, Uran, Raigad¹⁻⁴

Incharge Principal, Anjuman Islam College, Murud⁵

Assistant Professor, Veer Wajekar ASC Collage Phunde, Uran, Raiga⁶

Principal, Veer Wajekar ASC Collage Phunde, Uran, Raigad⁷

Abstract: *Benzimidazole derivatives play a crucial role in the field of medicinal chemistry due to their diverse pharmacological properties, including antibacterial, antifungal, anthelmintic, antiviral, antidiabetic, and anticancer activities. As a fused heterocyclic system containing both benzene and imidazole rings, benzimidazole has garnered significant attention in modern drug discovery and development. Its structural versatility and broad-spectrum bioactivity make it a valuable scaffold for the design of novel therapeutic agents. This review highlights recent advancements in the chemistry and pharmacological potential of benzimidazole derivatives, emphasizing their significance in the development of new drugs...*

Keywords: Benzimidazole, pharmacological properties, drug discovery, antibacterial, antifungal, antiviral, anticancer, anthelmintic, antidiabetic

I. INTRODUCTION

Benzimidazole is a distinct heterocyclic aromatic compound that holds a privileged position in medicinal chemistry as a crucial pharmacophore. Structurally, it is a bicyclic system formed by the fusion of benzene and imidazole rings, contributing to its remarkable pharmacological versatility. Benzimidazole derivatives have gained widespread attention due to their extensive range of bioactive properties.

The first benzimidazole derivative was synthesized by Hobecker in 1872. Subsequent research significantly expanded its medicinal relevance. In 1943, Goodman and Nancy Hart explored its pharmacological properties, while in 1944, Woolley reported the antibacterial potential of certain benzimidazole derivatives. Later, in 1949, Norman GB and Karl Folker identified 5,6-dimethyl benzimidazole as a degradation product following the acid hydrolysis of vitamin B12. These findings laid the foundation for extensive studies, establishing benzimidazole as an essential heterocyclic system with broad-spectrum biological activities.

Benzimidazole derivatives have demonstrated therapeutic potential against a wide range of diseases and pathogens. They exhibit diverse pharmacological effects, including antiviral, anticancer, anthelmintic, anti-inflammatory, analgesic, antihistaminic, antiparasitic, anticonvulsant, antiulcer, antihypertensive, antifungal, and proton pump inhibitory activities. Due to their broad therapeutic spectrum and significant clinical applications, benzimidazole derivatives continue to be a focal point in drug discovery and development.

BIOLOGICAL ACTIVITY OF BENZIMIDAZOLE: ANTIBACTERIAL ACTIVITY


The growing concern over bacterial resistance has driven significant interest in the development of novel antibacterial agents. Among these, 2-substituted benzimidazole derivatives have emerged as particularly potent candidates, making them a promising focus for antimicrobial drug development. Literature studies indicate that these derivatives exhibit enhanced pharmacological activity and are structurally present in several established antibacterial drugs, such as furacillin, furazolidone, and ftivazide.





Hydrazone derivatives have also garnered considerable attention in recent years due to their potential as chemotherapeutic agents in the design of new antimicrobial compounds. Notably, 1,2-disubstituted 1H-benzimidazole-N-alkylated-5-carboxamide derivatives have demonstrated significant antibacterial efficacy, particularly against methicillin-resistant *Staphylococcus aureus* (MRSA) and other *S. aureus* strains. These findings highlight the critical role of benzimidazole-based compounds in the ongoing search for effective antibacterial therapies

Clemizole peniciline

BIOLOGICAL ACTIVITY OF BENZIMIDAZOLE: ANTHELMINTIC ACTIVITY



Benzimidazole derivatives have been extensively developed and widely utilized as anthelmintic agents. Notable examples include albendazole, cyclobendazole, fenbendazole, flubendazole, mebendazole, oxi-bendazole, oxfendazole, and thiabendazole, all of which have demonstrated significant efficacy in treating parasitic infections. Faruk et al. synthesized a series of 5-nitro benzimidazole derivatives and evaluated their anthelmintic activity against the adult Indian earthworm (*Pheretima posthuma*). Their preliminary biological studies confirmed that all tested compounds exhibited remarkable anthelmintic effects. Similarly, Vilasrao et al. reported the synthesis of a library of 2-substituted benzimidazoles and assessed their anthelmintic potency against the adult earthworm *Eisenia fetida*. Among the tested compounds, several displayed exceptional anthelmintic properties, comparable to the standard drug albendazole. Additionally, benzimidazole derivatives were synthesized via the condensation of *O*-phenylenediamine and subsequently evaluated for their anthelmintic potential. The results indicated that these compounds exhibited significantly higher anthelmintic activity than the standard reference drug, piperazine citrate, reinforcing the therapeutic importance of benzimidazole-based agents in antiparasitic treatments.





Albendazole	Cyclobendazole
	

ANTIULCER ACTIVITY:

Benzimidazole derivatives have been widely explored for their antiulcer properties, particularly due to their ability to inhibit H^+/K^+ ATPase, a key enzyme in gastric acid secretion (3,4). Given their clinical relevance in treating peptic ulcers and other gastrointestinal conditions, researchers have developed more selective and potent benzimidazole-based proton pump inhibitors (4,5). In 1991, modifications to the benzimidazole core, such as N-H substitution with electron-donating groups and the addition of propyl acetamido-thio, thiazole-amino, and tetramethyl piperidine on pyridine, resulted in improved antiulcer efficacy (5). Common benzimidazole-based antiulcer drugs include omeprazole (a



racemic mixture), lansoprazole, rabeprazole, pantoprazole, and esomeprazole (S-enantiomer) (6). Omeprazole, in particular, requires an enteric-coated formulation to prevent degradation in stomach acid, and its effectiveness is linked to the transformation of its N-H substituent into a sulfonamide (6).



<p>Omeprazole</p> 	<p>Lansoprazole</p> 
<p>Pantoprazole</p> 	<p>Rabeprazole</p> 

ANTIMALARIAL ACTIVITY:

Malaria remains a major global health concern, causing approximately 350–500 million clinical cases and over one million deaths annually. The highest mortality rates are observed in sub-Saharan Africa, particularly among children under five. It is the fifth leading cause of death due to infectious diseases, following tuberculosis, respiratory infections, HIV/AIDS, and diarrheal diseases. An estimated 3.3 billion people across 109 countries live in malaria-prone regions, making it a widespread threat. Beyond its health implications, malaria significantly hampers the economies of affected nations, perpetuating poverty. The 1980s witnessed a surge in malaria cases and fatalities due to multiple factors, including humanitarian crises in endemic regions, the decline of traditional malaria control programs, ineffective integration into struggling primary healthcare systems, and the growing resistance of parasites and vectors to available antimalarial drugs and insecticides.

ANTICANCER ACTIVITY :

Cancer is the second leading cause of death in the United States and remains a significant global public health challenge. It is characterized by the uncontrolled growth and spread of abnormal cells, which, if left unchecked, can be fatal. Benzimidazole, a nitrogen-containing heterocyclic compound, plays a crucial role in cancer treatment. Several benzimidazole-based drugs have been developed, including bendamustine for chronic lymphocytic leukemia (CLL), veliparib as a PARP inhibitor, selumetinib targeting MEK1/2, galeterone for prostate cancer, and nocodazole, which disrupts microtubule dynamics and prevents tumor cell mitosis. Researchers continue to explore new and more effective anticancer agents to address issues such as toxicity, drug resistance, and specificity. The benzimidazole framework is recognized for its strong anticancer potential, making it a valuable structure for designing novel drug candidates. In particular, 2-substituted benzimidazoles, including 2-aryl and 2-heteroaryl derivatives, have gained attention for their promising anticancer properties, with bisbenzimidazoles demonstrating significant cytotoxic effects against various cancer cell lines.

<p>Veliparib</p> 	<p>Bendamustine</p> 
--	--



ANTIPROTOZOAL ACTIVITY:


Studies have reported that benzimidazole derivatives, including 5,6-dinitro and thioalkyl or thioaryl-substituted compounds, exhibit significant antimicrobial activity, particularly against *Stenotrophomonas maltophilia*. These compounds are effective against both Gram-positive and Gram-negative bacteria, functioning similarly to metronidazole. Additionally, 2-trifluorobenzimidazole derivatives have been identified for their biological activity, including previously documented anti-giardial properties. In a separate study, Phillips synthesized a series of 2-(trifluoromethyl)-1H-benzimidazole derivatives through the cyclocondensation of substituted 1,2-phenylenediamine with trifluoroacetic acid. These compounds exhibited potent nanomolar activity against several protozoan parasites, including *Giardia intestinalis*, *Entamoeba histolytica*, *Trichomonas vaginalis*, and *Leishmania mexicana*. Furthermore, their effectiveness was confirmed in *Trichinella spiralis* infections through both in vitro and in vivo testing.

ANTIVIRAL ACTIVITY:

Research indicates that benzimidazoles exhibit antiviral activity against *Enterovirus*, *Picornavirus*, and *Poliovirus*. Additionally, N-substituted benzimidazoles have been found effective against the *Tobacco Mosaic Virus*. Another reported approach involves synthesizing benzimidazole heterocycles with an amidino group at the C-5 position. In a published study, several novel benzimidazole derivatives were designed, synthesized, and evaluated in VERO cells for their inhibitory effects on four different enteroviruses. Among them, (L)-2-(pyridin-2-yl)-N-(4-nitrophenyl)pentan-3-yl)-1H-benzimidazole-4-carboxamide demonstrated the highest potential, exhibiting a strong antiviral effect along with a remarkable selectivity index.

ANTIHYPERTENSIVE ACTIVITY:

Biphenylbenzimidazoles have been found to possess a stronger antihypertensive effect compared to earlier similar drugs, primarily due to their improved oral bioavailability. The 2-position of the biphenyl structure plays a crucial role in their activity. Studies have also shown that 4'- and 5-substituted aryl or alkyl carboxamido derivatives act as antagonists of the Angiotensin-II AT1 receptor, making them effective agents for managing hypertension.



Benzimidazole is a key pharmacophore in modern drug discovery, and its derivatives have gained significant attention as potential antimicrobial agents. These compounds play a valuable role in medical research, with numerous studies highlighting the pharmacological potential of heterocycles and substituted benzimidazoles. As structural isosteres of nucleotides, they interact efficiently with biopolymers while exhibiting lower toxicity. Researchers are currently focused on developing more potent benzimidazole derivatives with diverse biological activities.

REFERENCES

- [1]. Cong, C., Wang, H., Huc, C., Ma, S., Li, X., Cao, J., Ma, S. (2011). Synthesis and antibacterial activity of novel 400-O-benzimidazolyl clarithromycin Derivatives. Eur. J. Med. Chem. 46:3105-3111. DOI PMid:21524827.



- [3]. Vilasrao JK, Manish BS, Deepali MJ, Priyanka SG, Priyanka LG. Synthesis and anthelmintic activity of novel benzimidazole derivatives. *Int J Res Pharm Chem* 2012;2:105-12
- [4]. Carcanague, D.; Shue, Y.K.; Wuonola, M.A. Novel structures derived from 2-[[[(2-pyridyl) methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2.
- [5]. *J. Med. Chem.*, 2002, 45, 4300-4309.
- [6]. Lindberg, P.; Nordberg, P.; Alminger, T.; Bradstrom, A.; Wallmark, B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. *J. Med. Chem.*, 1986, 29, 1327-1329.
- [7]. Grassi, J.I.; Bruno, M.; Thomas, G. BAY P 1455, A thiazolylaminobenzimidazole derivative with gastroprotective properties in the rat. *Eur. J. Pharmacology*, 1991, 195, 251-259
- [9]. Kosaka, N.; Tanaka, H.; Tomaru, A.; Ishii, A.; Shuto, K. Effects of KW-5805, a new antiulcer agent, on experimental gastric and duodenal ulcers, gastric mucosal lesions by necrotizing agents and gastric and secretion. *Jpn. J. Pharmacol.*, 1994, 65, 305-312
- [10]. Fang, B., Zhou, C.H., Rao, X.C. (2010). Synthesis and biological activities of novel amin-derived bis-azoles as potential antibacterial and anti-fungal agents. *Eur. J. Med. Chem.* 45:4388-4398. DOI PMid:2059399
- [12]. Camcho J., Barazarte A., Gamboa N., Rodrigues J., Rojas R., Vaisberg A., Gilman R., Charris J. (2011). Synthesis and biological evaluation of benzimidazole-5- Carbohydrazide derivatives as anti-malarial, cytotoxic and anti-tubercular agents. *Bioorg. & Med. Chem.* 19: 2023- 2019. DOI
- [13]. Siegel, R. L; Miller, K. D.; Jemal, A. Cancer Statistics, 2019. *CA. A Cancer J. Clin.* 2019, 69 (1), 7 – 34.
- [14]. Street, W. Cancer Facts & Figures 2020. 2020, 76.
- [15]. Kanwal, A.; Saddique, F.A.; Aslam, S.; Ahmad, M.; Zahoor, A.F.; Mohsin, N.-A. Benzimidazole Ring System as Privileged Template for anticancer Agents. *Pharm. Chem. J.* 2018, 51 (12), 1068-1077.
- [16]. Purushottamachar, P.; Ramalingam, S.; C.O. Njar, V. Development of Benzimidazole Compounds for Cancer Therapy. In *Chemistry and Applications Benzimidazole and its derivatives*; Marinescu, M., Ed.; IntechOpen, 2019.
- [17]. Hoy, S. M. Bendamustine: A Review of its Use in the Management of Chronic Lymphocytic Leukaemia, Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma and Multiple Myeloma. *Drugs* 2012, 72 (14), 1929-1950
- [18]. 1929-1950
- [19]. Wagner, L. Profile of Veliparib and Its Potential in the Treatment of Solid Tumors. *Onco Targets Ther.* 2015, 1931.
- [20]. Decaudin, D.; EL Botty, R.; Diallo, B.; Massonnet, G.; Fleury, J.; Naguez, A.; Raymondie, C.; Davis, E.; Smith, A.; Wilson, J.; Howes, C.; Smith, P. D.; Cassoux, N.; Piperno-Neumann, S.; Roman-Roman, S.; Nemati, F. Selumetinib-Based Therapy in Uveal Melanoma Patient- derived Xenografts. *Oncotarget* 2018, 9 (31), 21674-2168.
- [21]. McClurg, U.L.; Azzizyan, M.; Dransfield, D. T.; Namdev, N.; Chit, N. C. T. H.; Nakjang, S.; Robson, C. N. The Novel Anti-Androgen Candidate Galeterone Targets
- [22]. Deubiquitinating Enzymes, USP12 and USP46, to Control Prostate Cancer Growth and Survival. *Oncotarget* 2018, 9 (38), 24992-25007.
- [23]. Eilers, U.; Klumperman, J.; Huri, H. P. Nocodazole, a Microtubule-Active Drug, Interferes with Apical Protein Delivery in Cultured Intestinal Epithelial Cells (Caco2). *J. Cell Bio.* 1989, 108 (1), 13-22
- [24]. 1989, 108 (1), 13-22
- [25]. Kazimierzczuk Z, Upcroft JK, Upcroft P, Gorska A, Starosciak B and Agnieszka L. *Acta Biochimica polonica.* 2002;49:185-195.
- [26]. Navarrete-Vasquez G, Cedillo R, Hernandez-Campos A, Yopez L, Hernandez-leuis FJ, Valdez L, Morales R, Cortes M, and Castillo R. Synthesis and antiparasitic activity of 2-(trifluoromethyl) benzimidazole IJRPC 2011, 1(3) Ramanpreet et al. derivatives. *Bioorg Med Chem Lett.* 2001;11:187-190.



- [27]. Xiao L, Saeed K and Herd RP. Efficacy of albendazole and fenbendazole against Giardia Infection in cattle Vet. Parasitol. 1996;61:165-170.
- [28]. Katiyar SK, Gordon VR, McLaughlin GL and correlations with beta-tubulin sequence. Antimicrob Agents Chemother. 1994;38:2086-2090.
- [29]. Hernandez-Luis F, HernandezCampos A, Castillo R, NavarreteVazquez G, Soria-Arteche O, Hernandez Hernandez M and YepezMulia L. Synthesis and biological activity of 2-(trifluoromethyl)-1H benzimidazole derivatives against some protozoa and Trichinella spiralis. European Journal of Medicinal Chemistry.2010;45(7):3135-3141
- [30]. Eggers, Hans J, Tamm and Igor. Inhibition of enterovirus ribonucleic acid synthesis by 2-(alphahydroxybenzyl) benzimidazole. Nature. 1963;197:1327.
- [31]. Sullivan DG, Pantic D and Wallis AK. New 1, 2- disubstituted-benzimidazole derivatives. Ind J Chem. 2006;45(B):489-493.
- [32]. Tewari AK and Mishra A. Synthesis and antiviral activities of N substituted-2-substituted-benzimidazole derivatives. Ind J Chem. 2006;45(B):489-493.
- [33]. Starcevic K, and KarminskiZamola G. Synthesis, antiviral and antitumor activity of 2-substituted-5-amidino- benzimidazoles. Bioorg Med Chem. 2007;15(13):4419- 4426.
- [34]. Jat RK, Jat JL, Phatak DP. Synthesis of benzimidazole derivatives. As hypertensive agents. E-Journal of Chem.2006;3:278

